Mali vs Northern Africa and Western Asia: Percentage of bloodstream infection due to Escherichia coli resistant
Mali
60.9%
in 2022
Northern Africa and Western Asia
52.4%
in 2022
Mali rank
10th
Northern Africa and Western Asia rank
7th
Percentage of bloodstream infection due to Escherichia coli resistant over time
- Mali
- Northern Africa and Western Asia
How they compare
Mali currently reports 60.9% against 52.4% in Northern Africa and Western Asia, a difference of 8.5%.
That makes Mali's figure about 1.2 times Northern Africa and Western Asia's.
The two have swapped places 3 times across 5 shared years of data; in 2018 it was Northern Africa and Western Asia ahead.
Mali ranks 10th and Northern Africa and Western Asia ranks 7th of 50 countries.
Across the 2 decades both report, Mali averaged higher in 1 and Northern Africa and Western Asia in 1.
Head to head by decade
| Decade | Mali | Northern Africa and Western Asia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 35.9% | 54.7% | 18.8% | Northern Africa and Western Asia |
| 2020s | 56.0% | 53.7% | 2.3% | Mali |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher percentage of bloodstream infection due to escherichia coli resistant, Mali or Northern Africa and Western Asia?
- Mali, at 60.9% against 52.4% in Northern Africa and Western Asia as of 2022.
- What is the difference in percentage of bloodstream infection due to escherichia coli resistant between Mali and Northern Africa and Western Asia?
- 8.5%, with Mali ahead.
- How many years of comparable data are there for Mali and Northern Africa and Western Asia?
- 5 years are reported by both, from 2018 to 2022.
- How do Mali and Northern Africa and Western Asia rank globally for percentage of bloodstream infection due to escherichia coli resistant?
- Mali ranks 10th and Northern Africa and Western Asia ranks 7th of 50 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Percentage of bloodstream infection due to Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.